Current report filing

Note 23 - Supplemental Disclosure for Statements of Cash Flows (Details Textual)

v3.8.0.1
Note 23 - Supplemental Disclosure for Statements of Cash Flows (Details Textual) - USD ($)
 1 Months Ended 12 Months Ended
Mar. 31, 2015
Dec. 31, 2016
Dec. 31, 2015
Dec. 31, 2014
Jul. 15, 2014
Mar. 31, 2014
Interest Paid, Net   $ 5,500,000 $ 4,600,000 $ 2,900,000    
Stock Issued During Period, Shares, Employee Benefit Plan   67,002 68,157 36,455    
Issuance of Stock to Defined Contribution Plan for Employer Matching Contribution   $ 120,800 $ 117,099 $ 100,043    
Prepaid Insurance   348,000        
Notes Payable End of Term Fees     1,000,000 2,400,000    
Derivative Liability $ 63,000 63,000 63,000      
Preferred Stock Dividends and Other Adjustments   46,000    
R-NAV [Member]            
Equity Method Investment, Promissory Note Payable       666,666 $ 666,666  
Macrophage Therapeutics [Member] | Convertible Preferred Stock [Member]            
Preferred Stock Dividends and Other Adjustments $ 46,000   $ 46,000      
Capital Royalty Group, Term Loan [Member]            
Payments to Collection of Collateral on Claims of Default   778,000        
Payments to Prepayment Premium on Claims of Default   $ 2,100,000        
Note Payable to IPFS [Member]            
Debt Instrument, Interest Rate, Stated Percentage   8.99%        
Oxford Finance, LLC [Member]            
Debt Instrument, Interest Rate, Stated Percentage           8.50%
Warrants and Rights Outstanding       $ 465,000